Ryvu Therapeutics S.A. (WSE:RVU)

Ryvu Therapeutics Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	14.41	160.07	57.94	101.92	83.24	136.22
Short-Term Investments	-	65.86	175.73	0.53	4.99	24.97
Cash & Short-Term Investments	14.41	225.93	233.67	102.45	88.23	161.19
Cash Growth	-94.33%	-3.31%	128.09%	16.11%	-45.26%	123.54%
Accounts Receivable	77.6	15.66	9.19	1.05	5.94	2.2
Other Receivables	10.44	10.92	23.65	258.85	5.8	5.75
Receivables	88.04	26.58	32.84	259.89	11.74	7.95
Inventory	8.53	1.21	2.12	1.76	1.96	1.68
Prepaid Expenses	-	-	-	2.35	1.63	0.58
Other Current Assets	8.11	18.72	9.77	1.48	0.69	0.98
Total Current Assets	119.09	272.44	278.39	367.93	104.25	172.36
Property, Plant & Equipment	305.24	72.74	77.56	82.22	91.18	91.16
Long-Term Investments	60.05	16.77	34.37	20.48	29.4	29.12
Goodwill	89.13	-	-	-	-	-
Other Intangible Assets	26.22	8.12	6.34	4.28	3.04	2.32
Long-Term Deferred Tax Assets	17.88	-	-	-	0.33	0.59
Other Long-Term Assets	1.48	8.72	6.55	0.08	0.6	0.09
Total Assets	619.09	378.78	403.2	474.98	228.81	295.64
Accounts Payable	43.71	31.15	23.14	12.58	11.69	6.26
Accrued Expenses	11.17	12.28	12.22	11.7	4.86	5.31
Short-Term Debt	-	0.29	0.13	0.06	0.02	0
Current Portion of Long-Term Debt	29.74	25.79	-	0.81	0.81	0.81
Current Portion of Leases	31.6	0.5	0.41	1.03	1.92	2.27
Current Income Taxes Payable	0.22	-	-	-	5.46	-
Current Unearned Revenue	6.2	35.71	31.53	16.71	8.95	14.56
Other Current Liabilities	-0	2.21	2.27	1.93	2.5	4.6
Total Current Liabilities	122.64	107.93	69.7	44.81	36.2	33.81
Long-Term Debt	85.1	82.56	8.85	9.9	8.86	1.55
Long-Term Leases	57.98	1.39	0.37	0.87	1.58	2.77
Long-Term Unearned Revenue	33.43	42.74	64.26	75.8	20.26	27.5
Long-Term Deferred Tax Liabilities	3.3	-	-	-	0.44	6.04
Other Long-Term Liabilities	-	-	-	0.06	0.06	-
Total Liabilities	303.25	234.89	143.61	131.59	67.51	71.92
Common Stock	14.68	9.25	9.25	7.34	7.34	7.34
Additional Paid-In Capital	86.45	519.75	519.75	279.06	279.06	279.06
Retained Earnings	127.01	-111.44	-0.01	92.1	175.88	261.54
Comprehensive Income & Other	87.7	-273.67	-269.39	-35.12	-300.99	-324.22
Total Common Equity	315.84	143.88	259.59	343.39	161.3	223.72
Shareholders' Equity	315.84	143.88	259.59	343.39	161.3	223.72
Total Liabilities & Equity	619.09	378.78	403.2	474.98	228.81	295.64
Total Debt	204.42	110.53	9.76	12.67	13.19	7.41
Net Cash (Debt)	-190.01	115.4	223.91	89.77	75.04	153.78
Net Cash Growth	-	-48.46%	149.42%	19.63%	-51.20%	144.52%
Net Cash Per Share	-8.22	4.99	9.78	4.89	4.09	9.17
Filing Date Shares Outstanding	18.36	23.12	23.12	23.12	18.36	18.36
Total Common Shares Outstanding	18.36	23.12	23.12	23.12	18.36	18.36
Working Capital	-3.55	164.51	208.69	323.12	68.05	138.55
Book Value Per Share	17.21	6.22	11.23	14.85	8.79	12.19
Tangible Book Value	200.49	135.77	253.26	339.11	158.26	221.4
Tangible Book Value Per Share	10.92	5.87	10.95	14.67	8.62	12.06
Land	-	7.47	7.47	7.47	7.47	7.47
Buildings	-	52.21	52.2	52.15	53	48.33
Machinery	-	16.09	15.38	14.15	13.8	13.11
Construction In Progress	-	0.35	-	-	0.61	4.58

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.